Literature DB >> 18288403

BAG-1 inhibits PPARgamma-induced cell death, but not PPARgamma-induced transcription, cell cycle arrest or differentiation in breast cancer cells.

Simon J Crabb1, Angela Hague, Peter W M Johnson, Graham Packham.   

Abstract

BAG-1 is a pleiotropic protein that exists as multiple isoforms. BAG-1 overexpression in breast cancer is associated with outcome. BAG-1 modulates the function of various nuclear hormone receptors, including the oestrogen receptor, and BAG-1 can influence the in vitro action of anti-hormonal therapies such as cyproterone acetate in prostate cancer. Activation of PPARgamma, a nuclear hormone receptor important for lipid and glucose homeostasis, may present a new therapeutic approach for breast cancer, since PPARgamma agonists promote cell cycle arrest, differentiation and apoptosis in breast cancer cells. Here we determined whether BAG-1 also modulated PPARgamma function in MCF7 cells. 15-deoxy-Delta12, 14-prostaglandin J(2) (15dPGJ2), an agonistic ligand for PPARgamma, induced expression of HSP70, a BAG-1 binding partner, but did not alter BAG-1 isoform expression. Overexpression of BAG-1 isoforms did not alter PPARgamma-dependent transcription or interfere with 15dPGJ2-induced cell cycle arrest or differentiation. However, overexpression of BAG-1 isoforms did interfere with induction of cell death by 15dPGJ2. Thus, BAG-1 is unlikely to directly modulate PPARgamma function, but the overexpression of BAG-1 in some breast cancers may limit the efficacy of PPARgamma agonists as cancer therapies, by suppression of PPARgamma-induced cell death pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288403

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  3 in total

Review 1.  Multiple, but concerted cellular activities of the human protein Hap46/BAG-1M and isoforms.

Authors:  Ulrich Gehring
Journal:  Int J Mol Sci       Date:  2009-03-02       Impact factor: 6.208

Review 2.  PPAR gamma, bioactive lipids, and cancer progression.

Authors:  Gregory T Robbins; Daotai Nie
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

3.  LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models.

Authors:  Sergio Regufe da Mota; Sarah Bailey; Rosemary A Strivens; Annette L Hayden; Leon R Douglas; Patrick J Duriez; M Teresa Borrello; Hanae Benelkebir; A Ganesan; Graham Packham; Simon J Crabb
Journal:  Cancer Cell Int       Date:  2018-05-09       Impact factor: 5.722

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.